AVBP
ArriVent BioPharma, Inc. Common Stock
$26.73
-0.27
(-1.00%)
Mkt Cap
1.24B
Volume
425,358
52W Range
16.1-32.14
Sector
Healthcare
Beta
1.52
EPS (TTM)
-3.53
P/E Ratio
-4.65
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Net Income | (166.31M) | (80.49M) | (69.33M) | (36.91M) | (51.61M) |
| EPS | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| Free Cash Flow | (160.59M) | (70.21M) | (55.84M) | (43.63M) | (12.59M) |
| FCF / Share | -4.18 | -2.23 | -1.75 | -1.30 | -9.86 |
| Operating CF | (160.59M) | (70.21M) | (55.84M) | (43.63M) | (12.59M) |
| Total Assets | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Total Debt | 14,000 | 176,000 | 317,000 | 139,000 | 0 |
| Cash & Equiv | 45.54M | 74.29M | 150.39M | 163.37M | 37.28M |
| Book Value | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
| Return on Equity | -0.54 | -0.31 | -0.46 | -0.21 | -1.25 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.32M) | (35.54M) | (34.98M) | (31.40M) | (64.39M) | (20.63M) | (20.56M) | (21.87M) | (17.42M) | (21.19M) | (14.40M) | (21.57M) |
| EPS | -0.96 | -0.84 | -0.83 | -0.90 | -1.90 | -0.61 | -0.61 | -0.65 | -0.52 | -0.63 | -0.43 | -0.64 |
| Free Cash Flow | (41.89M) | (30.66M) | (35.80M) | (26.12M) | (68.01M) | (16.15M) | (16.34M) | (19.09M) | (18.63M) | (14.91M) | (15.44M) | (8.61M) |
| FCF / Share | -0.93 | -0.80 | -0.85 | -0.75 | -2.01 | -0.48 | -0.49 | -0.57 | -0.56 | -0.45 | -0.46 | -0.26 |
| Operating CF | (41.89M) | (30.66M) | (35.80M) | (26.12M) | (68.01M) | (16.15M) | (16.34M) | (19.09M) | (18.63M) | (14.91M) | (15.44M) | (8.61M) |
| Total Assets | 349.30M | 333.17M | 326.56M | 269.51M | 215.50M | 274.94M | 292.71M | 308.86M | 327.84M | 163.10M | 181.99M | 198.84M |
| Total Debt | 419,000 | 14,000 | 56,000 | 98,000 | 138,000 | 176,000 | 353,000 | 250,000 | 285,000 | 317,000 | 44,000 | 76,000 |
| Cash & Equiv | 62.10M | 45.54M | 112.67M | 112.77M | 49.87M | 74.29M | 282.86M | 298.67M | 317.39M | 150.39M | 141.36M | 157.83M |
| Book Value | 323.98M | 307.22M | 305.00M | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M | 317.72M | 151.30M | 171.89M | 186.03M |
| Return on Equity | -0.13 | -0.12 | -0.11 | -0.13 | -0.32 | -0.08 | -0.07 | -0.07 | -0.05 | -0.14 | -0.08 | -0.12 |
AVBP News
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
ArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?